CCM
ZYME icon

Coldstream Capital Management’s Zymeworks ZYME Stock Holding History

Coldstream Capital Management’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-129
Closed -$1.54K – 3435
2025
Q1 		$1.54K Buy
+129
New +$1.76K ﹤0.01% 3081

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Coldstream Capital Management's ZYME Position: Q2 2025 in Review

Coldstream Capital Management sold out of Zymeworks (ZYME) in Q2 2025, closing a stake of 129 shares — an estimated $1.54K sold.

Coldstream Capital Management first reported a position in ZYME in Q1 2025 and held it in 1 quarter. The position peaked at $1.54K in Q1 2025. 181 funds tracked by Wall St. Rank hold ZYME as of Q2 2025.

  • Coldstream Capital Management reported no remaining Zymeworks position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 129 Zymeworks shares in Q2 2025, an estimated $1.54K.
  • Coldstream Capital Management first reported a position in Zymeworks in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Zymeworks position peaked at $1.54K in Q1 2025.
  • 181 funds tracked by Wall St. Rank held Zymeworks as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.